SCHEMBL5151364

SCHEMBL5151364

O=C1CSC(c2cccc(OC(F)(F)F)c2)N1CCc1cccnc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
ALDH1A1 P00352 1/20 0.55
CACNA1B Q00975 1/20 0.49
POLB P06746 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
KCNH2 Q12809 1/20 0.46
SCN5A Q14524 1/20 0.46
SCN9A Q15858 1/20 0.46
KCNA5 P22460 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
PIM1 P11309 1/20 0.44
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KCNN4 O15554 1/20 0.43
GRM2 Q14416 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5156372 0.99 MAPT (0.54) MAPTALDH1A1CACNA1BPOLBNPSR1
SCHEMBL5152821 0.89 CACNA1B (0.53) MAPTALDH1A1CACNA1BPOLBNPSR1
SCHEMBL5149413 0.85 SMN1; SMN2 (0.56) MAPTCACNA1BTDP1KCNA5SMN1; SMN2
SCHEMBL5156994 0.85 MAPT (0.56) MAPTALDH1A1CACNA1BPOLBNPSR1
SCHEMBL5153130 0.85 KCNA5 (0.50) MAPTALDH1A1CACNA1BPOLBNPSR1
SCHEMBL5151549 0.82 MEN1 (0.48) MAPTKCNH2SCN5ASCN9AKCNA5
SCHEMBL5156906 0.81 CACNA1B (0.48) MAPTCACNA1BPOLBNPSR1KCNA5
SCHEMBL5154974 0.81 HCRTR1 (0.50) MAPTCACNA1BPOLBNPSR1TDP1
SCHEMBL5152128 0.81 ALDH1A1 (0.48) MAPTALDH1A1CACNA1BNPSR1TDP1
SCHEMBL5156907 0.81 KMT2A (0.60) MAPTALDH1A1POLBNPSR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 MAPT 3411/4885ALDH1A1 3381/4885CACNA1B 13/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MAPT 2432/4885ALDH1A1 1370/4885CACNA1B 10/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MAPT 2432/4885ALDH1A1 1370/4885CACNA1B 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.